Abstract: The present invention provides a formulation having excellent solubility and/or stability of a macromolecular drug, and more specifically, a pharmaceutical composition containing a macromolecular drug, a dissolution-enhancing and/or stabilizing agent, and an aqueous solvent, wherein the dissolution-enhancing and/or stabilizing agent is at least one selected from the group consisting of (1) proteins, (2) synthetic polymers, (3) sugars or sugar alcohols, (4) inorganic salts, (5) amino acids, (6) phospholipids, (7) aliphatic alcohols, (8) medium-chain fatty acids, and (9) mucopolysaccharides.

Abstract: The present invention provides a novel macromolecular drug, more specifically, a complex comprising a styrene-maleic acid copolymer (SMA) and a boric acid compound, wherein the SMA is bound to the boric acid compound directly or through a linker.

Abstract: According to an aspect of the present invention, there is provided a light radiating probe which is flexible and uniformly radiates light emitted from a light scattering and radiating portion at all azimuth angles of 360° so as to enable the simultaneous radiation of light to cancers disposed at a plurality of places scattered in a wide region. The light radiating probe for photodynamic therapy according to the present invention includes an optical fiber which extends in an axial direction and through which light from a light source propagates, in which the optical fiber has a light guide portion which is formed by forming thin film cladding on a side surface of a flexible core, and a light scattering and radiating portion which is configured to scatter, with uniform intensity, light propagating through the light guide portion to a periphery of the light scattering and radiating portion in all azimuth angles with respect to an axial direction of the flexible core.

Abstract: The present invention provides a formulation having excellent solubility and/or stability of a macromolecular drug, and more specifically, a pharmaceutical composition containing a macromolecular drug, a dissolution-enhancing and/or stabilizing agent, and an aqueous solvent, wherein the dissolution-enhancing and/or stabilizing agent is at least one selected from the group consisting of (1) proteins, (2) synthetic polymers, (3) sugars or sugar alcohols, (4) inorganic salts, (5) amino acids, (6) phospholipids, (7) aliphatic alcohols, (8) medium-chain fatty acids, and (9) mucopolysaccharides.